Mini kidney models to identify potential drugs for polycystic kidney disease

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-07-11 04:30 GMT   |   Update On 2022-07-11 10:15 GMT
Advertisement

USA: In a new study in Cell Stem Cell, scientists from the USC laboratory have generated simple kidney-like structures called organoids and used them to identify potential drugs to treat adult-onset polycystic kidney disease.

Polycystic kidney disease, presents an "autosomal dominant" pattern of inheritance meaning that the disease develops when a person inherits a bad copy of the gene PKD1 or PKD2, and the activity of the second good copy is also lost.

Autosomal dominant polycystic kidney disease (ADPKD) causes large fluid-filled cysts in many regions of the kidney, leading to the loss of kidney function and other life-threatening complications affecting the liver, pancreas, and heart. Tolvaptan, the only FDA approved drug to treat Autosomal dominant polycystic kidney disease, slows but does not block disease progression, and only works in a subset of cysts composed of a particular kidney cell type.

The scientists demonstrated that the organoids contained many of the cellular precursors and genetic signatures required to build the kidney during embryonic development. When implanted into a mouse, the organoids' nephron-like structures started to develop vasculature and even attained a limited capacity to filter wastes, one of the most important functions of the kidney.

To make the organoids useful for studying Autosomal dominant polycystic kidney disease, the scientists used CRISPR/Cas9 gene editing to inactivate PKD1 or PKD2. As anticipated, the gene-edited organoids began to form cysts, which eventually detached and grew to centimeters in diameter.

The scientists then performed the first screen using gene-edited human organoids to identify potential therapeutic drugs for ADPKD, focusing on a collection of enzyme inhibitors to give a broad insight into the cellular mechanisms controlling cyst formation.

After testing a collection of 247 enzyme inhibitor compounds on the organoids, the scientists found nine that inhibited the growth of the cysts, without stunting the overall growth of the organoids. One compound, quinazoline, was particularly effective.

"In the future, organoids will become an increasingly powerful tool for modeling and understanding human disease, identifying potential treatments, and eventually, providing transplants to replace organ function for patients concluded the researchers.

Reference: Tracy Tran, Cheng Jack Song, Trang Nguyen,Nils O. Lindström, Daniel C.-H. Lin,Andrew P. McMahon; DOI:https://doi.org/10.1016/j.stem.2022.06.005

Full View
Tags:    
Article Source : Cell Stem Cell

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News